『Key Findings of the NIAGARA and HIMALAYA Trials』のカバーアート

Key Findings of the NIAGARA and HIMALAYA Trials

Key Findings of the NIAGARA and HIMALAYA Trials

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.


Key Findings of the NIAGARA and HIMALAYA Trialsに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。